ID
29550
Description
Study ID: 102932 Clinical Study ID: HZA102932 Study Title:An open-label, randomised, 3-way crossover single dose study to demonstrate dose proportionality of fluticasone furoate (FF) and equivalence of vilanterol (VI) when administered as FF/VI inhalation powder from the novel dry powder inhaler in healthy subjects. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01213849 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: fluticasone furoate Trade Name: Allermist,Veramyst,Avamys; Veramyst,Avamys,Allermist Study Indication: Asthma Documentation part: LOGS and Repeats
Keywords
Versions (2)
- 3/10/18 3/10/18 -
- 4/5/18 4/5/18 -
Copyright Holder
GlaxoSmithKline
Uploaded on
April 5, 2018
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
GSK Dose proportionality of fluticasone furoate and equivalence of vilanterol in healthy adults NCT01213849
Similar models
LOGS and Repeats
- StudyEvent: ODM
C0877248 (UMLS CUI-2)
C0008976 (UMLS CUI-3)
C1320722 (UMLS CUI-4)
C0018941 (UMLS CUI [1,2])
C0200345 (UMLS CUI [1,3])
C0200345 (UMLS CUI [1,2])
C0031327 (UMLS CUI [1,2])
C0008000 (UMLS CUI [1,2])
C0587081 (UMLS CUI [1,3])